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ABSTRACT
PREDICTION OF CONCURRENT HYPERTENSIVE DISORDERS IN PREGNANCY AND
GESTATIONAL DIABETES MELLITUS USING MACHINE LEARNING TECHNIQUES
by
Mary O. Ejiwale
The University of Wisconsin-Milwaukee, 2021
Under the Supervision of Professor: Susan McRoy, PhD
Gestational diabetes mellitus and hypertensive disorders in pregnancy are serious
maternal health conditions with immediate and lifelong mother-child health consequences. These
obstetric pathologies have been widely investigated, but mostly in silos, while studies focusing
on their simultaneous occurrence rarely exist. This is especially the case in the machine learning
domain. This retrospective study sought to investigate, construct, evaluate, compare, and isolate
a supervised machine learning predictive model for the binary classification of co-occurring
hypertensive disorders in pregnancy and gestational diabetes mellitus in a cohort of otherwise
healthy pregnant women. To accomplish the stated aims, this study analyzed a sub-sample
(n=4624, n_features=38) of a labelled maternal perinatal dataset (n=9967, n_fields=79) collected
by the PeriData.Net® database from a participating community hospital in Southeast Wisconsin
between 2013 and 2018. The datasets were named, “WiseSample” and “WiseSubset”
respectively in this research. Thirty-three models were constructed with the following six
supervised machine learning algorithms: Logistic Regression, Random Forest, Decision Tree,
Support Vector Machine, StackingClassifier, and KerasClassifier (which is a deep learning
ii

classification algorithm). All the algorithms were evaluated using the StratifiedKfold crossvalidation (k=10) method. The Synthetic Minority Oversampling Technique was applied to the
training data to resolve the class imbalance that was noted in the sub-sample at the preprocessing
phase. Multiple feature selection techniques were explored to identify the best predictors of
concurrent hypertensive disorders in pregnancy and gestational diabetes mellitus. Model
performance quality was quantitatively evaluated and compared using accuracy, F1, precision,
recall, and the area under the receiver operating characteristic curve as metrics.
Support Vector Machine objectively emerged as the most generalizable model for
identifying the gravidae in WiseSubset who may develop concurrent hypertensive disorders in
pregnancy and gestational diabetes mellitus. The model obtained a recall score of 100.00%
(mean), with 9 predictors extracted by the recursive feature elimination with cross-validation
with random forest. Finding from this study show that using readily available routine prenatal
attributes, appropriate machine learning methods can reliably predict the co-existence of
hypertensive disorders in pregnancy and gestational diabetes mellitus. Six of the nine most
predictive factors of the comorbidity were also in the top 6 selections of at least one other feature
selection method examined. The six predictors are healthy weight prepregnancy BMI, mother’s
educational status, husband’s educational status, husband’s occupation in one year before the
current pregnancy, mother’s blood group, and mother’s age range between 34 and 44 years.
Insight from this analysis would support clinical decision making of the obstetric experts when
they are caring for 1.) the primigravidas since they would have no past obstetric history that
could prompt their care providers for related feto-maternal medical surveillance; and 2.) the
multigravidas with no previous pregnancy history that is suggestive of hypertensive disorders in
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pregnancy or gestational diabetes mellitus. Ultimately, the artificial-intelligence-backed tool
designed in this research would likely improve maternal-child care quality outcomes.
Keywords: Gestational Diabetes Mellitus, Hypertensive Disorders of Pregnancy,
Supervised Machine Learning, Deep Learning, Comorbidity, Concurrence.
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1. INTRODUCTION
1.1. OVERVIEW OF THE PROBLEM
1.1.1. OVERVIEW OF GESTATIONAL DIABETES MELLITUS AND HYPERTENSIVE
DISORDERS IN PREGNANCY

Gestational diabetes mellitus (GDM) and hypertensive disorders in pregnancy (HDP) are two
principal medical conditions that complicate pregnancy. They affect pregnant women of both the
developed and developing countries. These maternal health problems can occur alone or
simultaneously. Although both GDM and HDP have been widely studied, they have been
examined individually mostly, while their comorbidity is rarely investigated, especially with
machine learning (ML) methods. This research utilized five evidence-based standard supervised
machine learning (SML) algorithms, and a classifier from the deep learning (DL) sub-field of
SML for studying the co-existence of HDP and GDM (GDHP) affecting some otherwise healthy
pregnant women. The standard SML algorithms tested were Logistic Regression, Random
Forest, Decision Tree, Support Vector Machine, and StackingClassifier. Also, the DL algorithm
explored is the KerasClassifier.
Hypertensive disorders in pregnancy are a group of maternal health conditions previously known
as pregnancy-induced hypertension. It is characterized by a systolic blood pressure ≥140 mmHg
and/or a diastolic blood pressure at ≥90 mmHg taken at least on two occasions of 4 hours apart in
previously normotensive women [1] at or after 20 weeks of gestation. There are five main
variants of HDP: gestational hypertension pre-eclampsia (with and without severe features),
eclampsia, and HELLP (Hemolysis, Elevated Liver Enzymes and Low Platelet) syndrome. All
were present in the data analyzed in this research, and they were investigated collectively as
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HDP because studies have shown their risk factors are largely similar. Pregnancy is normally
associated with some hemodynamic changes and an impairment in such bodily modifications
may result in HDP [2]. Some of the maternal and child impacts of HDP are an increased risk for
future chronic hypertension [3] and cardiovascular disease for both mother [4] and child [5].
Chronic hypertension (which exists or is diagnosed before 20th week of pregnancy) and prepregnancy/pre-existing diabetes were excluded from this study. This exclusion is reasonable
since such medical histories are already a clear signal for the provider to institute “high risk”
pregnancy management. Also, postpartum hypertension (PHTN) is outside the scope of this
study, and a concurrence between PHTN and GDM is not meaningful since GDM is not a
postpartum diagnosis, and no data related to postpartum glucose test is in the analyzed dataset.
Gestational diabetes mellitus is the most common medical complication of pregnancy. Insulin
resistance and the accompanying compensatory hyperinsulinemia by the pancreatic β-cells are
some of the physiologic changes of pregnancy. However, some women experience an imbalance
in these normal processes, leading to gestational diabetes. GDM is a hyperglycemic condition
that starts newly (or is first diagnosed) at late pregnancy ≥24th week in an otherwise euglycemic
woman. This pregnancy complication is characterized by glucose intolerance, insulin resistance,
and hyperglycemia [5]. In terms of screening/evaluation there is no universal assessment
guideline currently for GDM [6]. Expectant mothers are usually screened for this health problem
between 24 and 28 weeks of pregnancy, using Oral Glucose Tolerance Test (OGTT) to evaluate
the efficiency of the body to metabolize glucose. Like its HDP counterpart, GDM has a plethora
of deleterious immediate and future maternal and child effects. These include an increased risk
for diabetes (both mother and offspring), early faster puberty for the child [7].
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1.1.2. OVERVIEW OF MATERNAL METABOLIC SYNDROME
Metabolic syndrome (MetSyn), previously known as Syndrome X (or insulin resistance
syndrome), has a significant relationship with HDP and GDM. A shared maternal impact of HDP
and GDM is their metabolic sequalae [8], and MetSyn may predict HDP [9], and/or gestational
diabetes [10]. Literature also indicates women’s sex roles (parturition-specific factors) such as
pregnancy, parity, lactation, contraception, and infertility treatment; influence the risk of
MMetSyn [11], [12], [13], [14]. The condition is characterized by a cluster of five major risk
factors, three of which are closely related to HDP and GDM. The established risk factors for
MetSyn are high body mass index; insulin resistance/ high blood glucose; high level of lowdensity lipoprotein, low level of high-density lipoprotein [dyslipidemia]; and high blood pressure
[15]. MetSyn is a grievous global health challenge with no regard for age, gender, or ethnicity.
The syndrome is defined by some national and international health bodies, including the World
Health Organization [16], International Diabetes Federation [17], and the National Cholesterol
Education Program Adult Treatment Panel III 2001 [18]. Even though these organizations differ
slightly in their full definitions of MetSyn, they are unanimous in including a measure of central
obesity, glucose metabolism, and blood pressure in their characterizations of the syndrome.
MetSyn has had increasingly wide scientific attention, but the general population is commonly
targeted [19], [20], [21]. This focus may have contributed to the lack of maternal metabolic
syndrome (MMetSyn) as an obstetric diagnosis, and thus a lack of an associated International
Classification of Diseases 9/10 (ICD Version 9/10) code, despite the association of MetSyn with
GDM, HDP and parturition. These issues about MetSyn of the pregnant women have also
resulted in a lack of easily accessible structured information about the health problem in
electronic health records of pregnant women that might allow one to easily extract related
3

dataset. This makes a direct, manual cohort analysis impractical. Instead, the research described
here considers the relationship between GDM, HDP and MetSyn, using a method that creatively
serves as a proxy for a retrospective cohort analysis where machine learning methods are applied
to predict maternal metabolic syndrome. Moreover, this innovative proxy study has a utility,
since GDM and HDP are well recognized diseases in the obstetric community than maternal
MetSyn, building a model for their comorbidity is more valuable to the study population and
their providers, than modelling MMetSyn that is yet to be established as a diagnosis. This type of
study is particularly useful with sophisticated methodology like machine learning; the kind
utilized in this research.
1.2. OVERVIEW OF THE DATASET
The PeriData.Net® database is a perinatal clinical data repository. It consists of individual-level
patient-identifiable data collected from the parents and the clinical record at participating
Wisconsin (WI) birth hospitals. The database was originally developed in the mid-2000s for
collecting Birth Certificate Data required by the Department of Health Statistics (DHS), with
additional information as requested by participating hospitals, the Wisconsin Association of
Perinatal Care (WAPC), and other stakeholders. Ultimately, DHS chose another program to
collect the data, but most of the birth hospitals in the state continue to use Peridata.net®18 because
there are valuable reporting formats provided by Ancilla, LLC; a company that is responsible for
the data collection and storage.
This research is being conducted using a dataset from a single hospital in a small urban
community in the Southeast WI for the period of 1/1/2015 to 2018. This sample contains 9962
instances with 79 fields, while its extract has 4624 instances with 38 fields. The omitted fields
included: 1.) primary fields that were combined during data extraction; 2.) fields with high
4

number of missing values (e.g., intrauterine growth retardation; 3.) fields with low frequency
count values that could not benefit from merging (father’s education for instance); 4.) fields
about/clearly suggestive of GDM/HDP-in the past obstetric history (“macrosomia_PreviousPreg”
for example); and 5.) redundant fields (for example, husband’s reported age and husband’s
calculated age fields have nearly the same number of actual values). Our research protocol
included two types of limited Protected Health Information (PHI): “Year of last birth” and “Date
of first prenatal visit” fields, which were added because the contained information that could be
used to derive some known risk factors of GDM and HDP. There were three types of values in
the sample- actual, missing, and placeholder. Also, the dataset format is heterogeneous, having a
disparate mix of numeric, and non-numeric types that could be mapped onto numeric format
during preprocessing. Some numeric fields in the dataset also have values that could be
manipulated into new fields to enable the identification of the specific/range of values associated
with GDHP; prepregnancy Body Mass Index (BMI) was one of such primary fields.
Additionally, the sub-sample dataset is significantly imbalanced for the outcome values.
1.3. OVERVIEW OF METHOD
A sample of PeriData.Net® database was analyzed in a retrospective cohort study that examined
a representative set of supervised machine learning algorithms for constructing several binary
classification models for identifying the GDHP-at-risk gravidae. The six classifier training
algorithms examined in this study were Logistic Regression (LReg), Random Forest (RF),
Decision Tree (DTree), Support Vector Machine (SVM), StackingClassifier (Stack), and
KerasClassifier (Keras), which is a deep learning method. During preliminary training and
testing, we generated several alternative sets of features using four well-known feature selection
techniques (FSTs). The following FSTs were applied 1.) Recursive Feature Elimination (RFE),
5

2.) Recursive Feature Elimination with Cross-Validation (RFECV), also known as ensemble
feature selection approach; 3.) Genetic Algorithm, and 4.) Pearson Correlation Coefficient and
Variance Inflation Factor Analyses (PCC-VIFA).
The impact of the features and the strategy that selected them were assessed through the
performance of models constructed with them. The quantitative quality metrics utilized for these
assessments were accuracy, F1, precision, recall, and the area under the receiver operating
characteristic curve (AUC), including a plot of the receiver operating characteristic curve (ROC).
1.4. OBJECTIVES, RESEARCH QUESTIONS, AND SPECIFIC AIMS
1.4.1. GENERAL OBJECTIVES OF THE STUDY
This study sought to construct, evaluate, and compare multiple supervised machine learning
(standard and deep) models for pregnant women who are at risk for concurrent gestational
diabetes mellitus and hypertensive disorders in pregnancy. The motivation behind the plan to
explore and compare multiple classification models is the idea that no single model performs
optimally across all problems; a phenomenon known as “No Free Lunch theorem” in the
machine learning domain. The problem of predicting the risk for maternal MetSyn was mapped
to a problem of developing a classifier to map the multi-facetted data of the gravidae to a binary
class outcome of Yes_GDHP or No_GDHP. For the analysis. we examined the data fields that
already exist in the dataset and some other fields that we engineered from them. All the models
were to be assessed quantitatively and compared for performance quality, using standard
measures of accuracy, F1, precision, recall (sensitivity), and the area under the receiver operating
characteristic curve (AUC) as metrics. The best performing model that generalized well to
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unseen data in the identification of the GDHP-at-risk instances was to be isolated, and the
following research questions were to be addressed:
1.4.2. RESEARCH QUESTIONS
1.4.2.1. RESEARCH QUESTION 1
Compared to genetic algorithm, does any of the feature selection techniques (Section 1.3)
better identify the best input data for building an SML model for GDHP with the dataset
in this analysis?
1.4.2.2. RESEARCH QUESTION 2
Could there be any GDHP model that can outperform the Keras model when assessed
with recall on the dataset to be analyzed in this study?
1.4.2.3. RESEARCH QUESTION 3
Would the Synthetic Minority Oversampling Technique (SMOTE) algorithm effectively
address the class imbalance problem that exists in the dataset?
These questions are answerable by the corresponding specific aims of the project (Section 1.4.3)
1.4.3. SPECIFIC AIMS OF THE STUDY
The specific aims are to 1.) assess the utility of the FSTs (Section 1.3) in identifying the most
relevant risk factors for modeling GDHP with SML techniques; 2.) utilize and compare multiple
SML algorithms (Section 1.3) in building GDHP models with the dataset; 3.) construct and
compare various SML models (Section 1.3) before and after the application of SMOTE on the
imbalanced dataset. These aims would lay the groundwork for assessing the feasibility of
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automated analyses, and for establishing the potential benefit of conducting studies with larger
datasets in the future.
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2. LITERATURE REVIEW AND RELATED STUDIES
2.1. LITERATURE REVIEW
2.1.1. BACKGROUND OF THE OBSTETRIC HEALTH PROBLEMS
Gestational diabetes mellitus and hypertensive disorders of pregnancy are common medical
conditions associated with pregnancy. The prevalence of HDP is 5.2-8.2% [22]. In a
multinational, multi-site research conducted in 2010-2012; where 214,070 women of 106
communities in 7 low and middle-income nations were studied, 16% (55) of the 335 women that
died had preeclampsia or eclampsia [23]. In Southeast Iran 31.9% of severe maternal morbidity
near misses [24]. The Centers for Disease Control and Prevention (CDC) indicates DHP
attributes to 6.6% of pregnancy and childbirth related deaths [25]. Gestational diabetes mellitus
on the other hand, is estimated to constitute 16.0% of the global prevalence of hyperglycemia in
pregnancy among women ages 20-49 (16.9%) [26]. Insulin resistance and the accompanying
compensatory hyperinsulinemia by the pancreatic β-cells are some of the physiologic changes of
pregnancy. However, an imbalance in these processes may result in a hyperglycemic condition
that starts newly (or is first diagnosed) in late pregnancy ≥24th week in the otherwise euglycemic
pregnant women. GDM and HDP are individually consequential pregnancy-associated health
conditions with immediate and lifelong maternal and fetal/child health impact. Mounting
evidence is available in literature pointing to the immediate and future (sequelae) maternal and
child health (MCH) effect of HDP and GDM.
2.1.1.1. MATERNAL AND CHILD IMPLICATION OF GESTATIONAL DIABETES
MELLITUS OR HYPERTENSIVE DISORDERS OF PREGNANCY
Pregnant women experiencing HDP may have an increased risk for chronic hypertension 5 years
postpartum [27], and cardiovascular disease for both mother [4], [28], and baby [5]. Post9

traumatic stress disorders [29]; salt hypersensitivity [30]; end-stage renal disease (increased risk
by 5- to-12-folds) [31], [32]; and metabolic syndrome [33] , [8] are also linked to HDP or GDM.
Infants born to pregnancy-related hypertensive or diabetic mothers are not spared of the short
and long-term effect of these disorders. The child impact includes the following: An increased
risk of cardiovascular disease [5]; and neuro-developmental impairment [34]; and future weight
problem [35]; metabolic syndrome [36]. Meanwhile, MetSyn increases the chance of the boy
child experiencing infertility in his adulthood [37]. Likewise, prematurity and birth weight
problems are also linked to HDP [38] and GDM [39]. In a ripple effect, female premature
babies/girls who had birth-weight problem have a high tendency of developing HDP or GDM
when pregnant [40] perpetuating the cyclic nature of the disorder. Other impacts of HDP/GDM
include neuro-developmental impairment [34], [41] and behavioral disorder [42].
2.1.1.2. COST IMPLICATION OF GDM OR HDP
Aside from the scores of maternal-fetal/child consequences of HDP and GDM, evidence abounds in the
literature showing these pregnancy-related medical conditions are also uneconomical. HDP alone incurs

additional care costs of $173 million annually [43], and the annual burden per case of GDM is
approximately $5,800 [44].
2.1.1.3. RISK FACTORS OF GDM OR HDP
The unpleasant, and sometimes life-threatening, effect of GDM or HDP is heightened when both
disorders co-exist, then, GDHP deserves additional scientific attention. Meanwhile, the exact
causes of GDM and HDP individually or jointly, are unknown, but related studies suggest
several factors explain them. It is worthwhile investigating such risk factors (and metabolic
syndrome) to understand and identify the strongest predictors of GDHP. Among the social
determinants of health influencing these pregnancy complications are smoking, alcoholism, and
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socio-economic factors [45], maternal height [46], parity [47], [12], gravidity [12], maternal
blood group [48], [49], [50], outdoor air/temperature [51], and genetics [52]. Research shows
prepregnancy obesity [53] is fundamental to these metabolic-related obstetric health problems.
Pre-conception weight/BMI is commonly based on the score obtained at the first prenatal care visit.

Obesity is a body mass index (BMI) ≥30 kg / m2, according to the CDC [54]. A substantial body
of evidence demonstrates the determinants of health influencing of GDM and HDP; including
their conjoint, is multifactorial, and while some risk factors are peculiar to the expectant mother,
the unborn child, and his/her biological father; others have genetic, environmental, or obstetric
components. Studies show assisted reproductive technology (ART) is also associated with
gestational hypertension and preeclampsia [55]. This assertion is supported by a large systematic
review of 47 related studies [56]. Additionally, a meta-analysis of twenty-six GDM studies with
120 million participants signifies mother’s age is crucial to the development of GDM or HDP,
but the study asserts that there is no agreement over the specific age/ age group associated with
GDM [57]. The role, and the precise maternal age/age group that is linked with GDHP is,
however, not yet established. Maternal height is a significant anthropometric measurement in
hypertensive disorders of pregnancy [58], and short people have a higher predisposition to GDM
[46]. It is unclear whether this factor influences the concurrence of both disorders. Central to
these maternal health problems is the obesity epidemics [14]. Studies indicate that, in the U.S.;
where metabolic syndrome surges [59], prepregnancy obesity deepens [12]. As shown in a recent
analysis of the Wisconsin Interactive Statistics on Health (WISH) data of the 2011–2014 period,
27.8% of WI mothers are obese [60]. Some pregnant women, however, may not know their
prepregnancy weight or BMI for reasons such as unintended pregnancy (>50.00% in the United
States [61]), hence, the commonest approach is the adoption of the first prenatal visit values of
these measurements. In a research that utilized animal model (rats), the results suggest exposure
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to air pollutants such as nicotine (first/secondhand) contributes almost one-third (30%) of
maternal obesity [62] and maternal metabolic conditions [14]. Other significant environmental
components influencing HDP/GDM occurrence are Particulate Matter 7 (PM7) vehicular emits
exposure [63], and urbanization [64]. Furthermore, there is evidence supporting the notion that
vitamin D; also known as 25-hydroxyvitamin D (25(OH)D), has a bearing on pregnancy
outcomes. The environment, genetics, and racial are a close- knit with this fat-soluble vitamin
that enhances glucose tolerance. Vitamin D deficiency (hypovitaminosis D), which is defined as
low serum 25-hydroxyvitamin D (25(OH) D) level [65], is prevalent worldwide [66], (among
women particularly). Maternal hypovitaminosis D raises the susceptibility to GDM and HDP
[67], [68]. This condition is, however, racially biased against the African Americans and their
high level of melanin is linked to the insufficiency [66]. This racial group is the worst hit of
preeclampsia [69] and maternal mortality in the United States [70]. Partner change is another
unconventional factor influencing HDP; preeclampsia especially [55], [58]. Access to care and
medical insurance [45]; and fetal gender [71] are some other dynamics influencing GDM and
HDP. It is therefore evident that the impact of GDM and HDP is both extensive and expensive,
and the coalesce of the disorders may escalate their individual devastating consequences. Also,
the challenges confronting the existing risk identification approaches are complicated. These
issues affirm the relevance of our research as it is of utmost importance to understand this serious
comorbidity from supervised machine learning perspective.
2.1.1.4. THE NEED FOR MACHINE LEARNING PREDICTIVE MODELS FOR GDHP
The cause(s) of gestational diabetes mellitus and hypertensive disorders in pregnancy remains
largely elusive, and their prevention is a challenge to the obstetric community [72]. There is lack
of direct laboratory test or a particular screening method designed for identifying the GDHP-at12

risk pregnant women; the test (including results) for each of the disease components of GDHP
may also reside across multiple silos screening; and the tests may have been done at different
times or places. Such disjoint screening is not only inconvenient for pregnant women, but also
resource-consuming (patient time, care cost; and hospital economy) for both patients and
providers. Some of the individual screening methods may still have limitations, as Gaillard et al.
(2018) [73] indicated about the African American women and metabolic syndrome screening.
Additionally, late GDM screening [74], and the variations of such screening [6] pose challenges to
the disease. Lack of agreement over laboratory tests threatens the quality of the procedure, and it

may endanger perinatal outcomes. Another issue with GDHP risk assessment currently is that early
clinical diagnosis is hampered by the mid (HDP) to late (GDM) manifestation of the clinical
symptoms of each of its disease components. Lastly, convoluted interactions exist among the
many factors associated with the comorbidity of HDP and GDM, and these interactions are not
only difficult to determine, but also too burdensome for most providers’ limited time. Therefore,
there is a great need for GDHP risk factor assessment automation through the machine-aided
approach that this study develops. Such a tool is scalable, and it would ameliorate the discussed
challenges with fewer resources. It would also be more convenient; requiring no patient effort,
and generate results instantaneously at the point of care, all in a feto-maternal non-invasive
manner. Moreover, because this study would identify which group of the gravidae have the
greatest risk of GDHP, and what the best predictors are, it offers insight into the care providers
and the stakeholders towards targeted and strategic program planning (prevention and early
intervention). This would ultimately save the associated cost from increasing morbidity and
mortality to the care of women and their infants. As advantageous as risk identification of GDHP
might be to perinatal outcomes, the comorbidity is rarely studied, relative to research
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investigating GDM and GDP individually, especially in the machine learning domain, therefore,
this research also adds to the body of knowledge.
Finding from this work would support clinical decision making of obstetric experts to identify
pregnant women who have a high risk for GDHP and thus might need more specialized care
management. The model will particularly be useful to them when caring for 1.) the primigravidas
since such women are carrying their first pregnancy, thereby, have no previous obstetric history
that could prompt their care providers for maternal and child medical surveillance; and 2.) the
experienced pregnant mothers (multigravidas) with no known obstetric history related to GDM,
HDP or GDHP. Therefore, the model will likely boost maternal and child care quality outcomes;
and ultimately be lifesaving for pregnant women and their unborn babies. Equally, the result of
the proposed study will potentially promote an effective targeted preventive/interventional
patient care plan; and proper resource distribution to the most needful because our model will
additionally identify the specific non-causal (risk) factors that best explain GDHP in a noninvasive manner.
2.1.2. BACKGROUND OF METHOD
The methods will examine the effectiveness of alternative automated methods for training
predictive models with existing data where the data elements correspond to the aggregated
clinical history of an individual patient, represented as a set of fields and associated values.
These methods will all be examples of supervised machine learning, because the (preprocessed)
data itself will provide examples of the class values to be predicted as an outcome, while the
other values might be used as features that might predict that outcome through some
combination. SML methods generally assume (or work best when) features are independent (and
thus cannot be redundant), values for features are always available, and the distribution of values
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is uniformly balanced across their ranges, which is not always the case for medical data.
To address the complexities of real data, methods of feature selection and feature augmentation
can be applied before the final SML models are created. SML models overall can be evaluated
using either a fixed split between training and test sets; or by using a variant of cross-validation,
which partitions the data over multiple evaluations (by random or stratified sampling technique),
each of which uses a different partition as the training and test sets.
2.1.2.1. FEATURE SELECTION
Feature selection picks the best subset of features that maximize the performance of the model.
Generally, this is done by evaluating different feature subsets- formed from leaving some out and
testing them. This means we will know what the features to use, but not what values for features
lead to each class in the decision problem. The aim of this procedure is to minimize the number
of selected features to the optimal ones that explain the model the most. Among other benefits,
feature selection removes redundant independent factors, while potentially preventing /
minimizing 1.) errors; 2.) computational cost of measurement; 3.) underfitting; 4.) overfitting.
The process also mitigates false or unreliable results. Feature selection adds value beyond model
accuracy because it provides meaningful insight into the data, making the results of SML more
transparent. Moreover, most modeling algorithms cannot efficiently handle high dimensional
data, hence, it is reasonable to eliminate features that offer no value to the model [75]. In an
imbalanced dataset, preceding data resampling with feature selection is suggested to be more
effective, especially, if using SMOTE [76]. Four FSTs assessed in this study are: Recursive
Feature Elimination, Recursive Feature Elimination with Cross-Validation, Pearson Correlation
Coefficient and Variance Inflation Factor Analyses, and Genetic Algorithm.
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2.1.2.1.1. RECURSIVE FEATURE ELIMINATION
RFE is an embedded FST that works with either deterministic (fixed) or stochastic
(random) threshold. The threshold is the number of reduced features (n_features) to be
used by the classifier. These cut off points serve as the stopping criteria for the iterations.
The algorithm uses a classifier; hence, each iteration produces a model accuracy, and the
index number of features is displayed alongside with the model accuracy. The algorithm
is slow, but it has a track record of success in studies such as the identification of gene
associated with myocardial infarction [77]. The authors explored RFE with SVM.
2.1.2.1.2. RECURSIVE FEATURE ELIMINATION WITH CROSS-VALIDATION
This is an ensemble feature selection approach. It aims is to identify and choose a unique
set of optimal features obtained from the combined selections of multiple FSTs. Hence,
the RFECV algorithm is a model based FST, thus operating through an estimator
(classifier). Any type of cross-validation method can be implemented in RFECV, but the
StratifiedKFold (SKFCV) is a robust cross-validation variant for imbalanced data through
its sampling technique (stratified). The three methods involved in the FST are available
through the Scikit Learn Application Programming Interface (API).
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2.1.2.1.3. GENETIC ALGORITHM
Genetic Algorithm belongs to the wrapper category of feature selection approaches. It is
an advanced biology-based (evolution) computational method that treats feature selection
as a search problem, searching iteratively to find the overall optimal set of values for
some parameter by generating new candidate combination (features) and evaluating them
together, such that by the final stages of the search, only the combinations that lead to the
highest quality results remain. This feature selector is widely used in computerized
modeling tasks involving medical problems. The algorithm also has an impressive
performance track record [78].
2.1.2.1.4. PEARSON CORRELATION COEFFICIENT
AND VARIANCE INFLATION FACTOR ANALYSES
This method involves three sequential steps 1.) feature-feature multicollinearity check;
2.) feature-target correlation analysis, and 3.) Variance Inflation Factor (VIF) analysis for
further assessed for multicollinearity assessment. Each step requires setting a threshold
for correlation coefficient (r), and an R-Squared threshold for VIF. The output of one step
is the input of the next step. The VIF method is an inverse of 1-(R- squared), and it is
available through the Scikit Learn or Statsmodel library of Python programming
language. The final output of VIF analysis becomes the selected features of the PCCVIFA feature selection technique.
Mathematically, VIF is expressed as: (1/(1-Ri^2))
,where Ri^2 is the amount of variance in y that is explained by x
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(1)

2.1.2.2. DATA AUGMENTATION
The Synthetic Minority Oversampling Technique is a data resampling algorithm that is
commonly used to resolve severe imbalances in the training set, such as when the number of
positive examples is less than a quarter of the total, which would allow a training algorithm to
achieve high measures of performance simply by defaulting to the majority class. There are
different strategies utilized by the resampling method, the default being “auto”, which ensures
the number of the minority class and that of the majority class are the same. The K-Neighbors
algorithm is the underpinning mechanism of the SMOTE algorithm (resampler). The default
value for the k_neighbors parameter (k) in SMOTE is 5. The resampler can be implemented
externally or internally through its Imblearn pipeline, and the algorithm can be optimized to
enhance its effectiveness.
2.1.2.3. MODEL OPTIMIZATION METHOD
2.1.2.3.1. HYPERPARAMETER TUNING
Hyperparameter optimization is a process of finding the best combination of model parameters
and their values towards minimizing errors and constructing an optimal model. Model
optimization can be performed manually or automatically. The GridSearchCV (GSCV), from
Scikit-Learn, is one of the algorithms that is commonly utilized to objectively tune (or regularize,
in the case of logistic regression) the hyperparameters of a given classifier. The user provides a
list of different hyperparameters and their corresponding values of a classifier to the “gridparam” parameter of the GSCV. The tuning algorithm then iterates over the list, and produce the
best combination of parameters, based on a specified model performance scoring metric. The
process is, however, time-consuming and the set of parameters (and their values) to explore are
based on user’s preference, leaving room for variation.
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A key parameter optimization in the Tree-based algorithms (RF and DTree) is the “criterion”,
which determines the type of method the algorithms use for finding the informativeness of each
feature in their decision making of class assignment. This concept is known as Information Gain
(IG) analysis. RF and DTree use two approaches (Gini and Entropy) for calculating feature
information gain, also known as feature importance. Entropy was selected by the GSCV method
for both tree-based algorithms in this study.
2.1.2.3.2. ENTROPY
Entropy is a measure of the informativeness of a given feature to the determination of the class
assignment by a Tree-based algorithm. Its score ranges between 0 and 1. The smaller the Entropy
score of a feature, the optimal the split at such node; and a given node is said to be pure when its
Entropy score = 0. When both classes in a binary classification obtain the same probability score
in a feature, a maximum Entropy (1) score is obtained, and the node is said to be “impure”,
implying uncertainty. Classifiers are often optimized to maximize purity and reduce errors.
Formula for Entropy:

, where p represents probability

(2a)

For our binarized target, RF and DT would compute the Entropy score of each feature as
follows:
Entropy=[(prob_Yes_GDHP)*log2(prob_Yes_GDHP)]-[(prob_No_GDHP)*log2(prob_No_GDHP)]
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(2b)

2.1.2.4. MODEL EVALUATION METHOD
2.1.2.4.1. STRATIFIEDKFOLD CROSS-VALIDATION METHOD
The StratifiedKFold cross-validation model evaluation method is a type of cross-validation (CV)
method that splits the dataset into k equal mutually exclusive stratified subsets, rather than
performing a random split as K-Fold cross-validation does. K-1 folds are then utilized for
training the model while each of the subsets is used exactly once for testing the predictive
performance of the model. This process is repeated (iteration) k-times, and the model
performance results per k-fold are then aggregated. The mean (average) value is the
generalization result per model evaluation metric. StratifiedKFold CV is a well-known model
evaluation approach when using an imbalanced data.
2.1.2.5. PIPELINE

Source: Dipanjan Sarkar, Raghav Bali, Tushar Sharma. Practical machine learning with Python (2018).

Figure 1: Standard supervised machine learning pipeline.
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Within the scope of standard machine learning, a pipeline (Figure 1) represents a clear workflow
(step-by-step) of a modeling task. Among other benefits, the use of a pipeline promotes model
scalability and updatability.
2.1.2.6. OVERVIEW OF THE SUPERVISED MACHINE LEARNING ALGORITHMS
EXPLORED
The predictive model of GDHP was established based on five standard SML classifiers and one
deep learning algorithm. The support vector machine, logistic regression, random forest, decision
tree and StackingClassifier were the standard SML algorithms tested, while the KerasClassifier
was examined from the DL subset of SML. The six algorithms were employed to automatically
differentiate whether a pregnant woman belongs to the positive class or the negative class
2.1.2.6.1. SUPPORT VECTOR MACHINE
Support vector machines are a distance-based method for training a classifier. The
method sets a decision boundary between examples represented as vectors such that the
distances between the examples (for either class) and the boundary are maximized. SVM
can handle both multiple continuous and categorical variables. Studies show the
algorithm often produces higher-performing models than other classification algorithms,
including decision tree, and the conventional statistical methods [79]. This classifier uses
regression to find and construct hyperplanes in a multidimensional space that best
separate cases of different class labels, binary labels in this case. The farther away a point
is from the separating line, the more confident one can be about the prediction for that
point. In a study of concurrent Type 2 diabetes mellitus and hypertension in the general
population, SVM was one of the two classifiers with outstanding performance [80].
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2.1.2.6.2. LOGISTIC REGRESSION
Logistics Regression, also known as logit, is a statistics-based supervised machine learner
that is used both in classification and regression problems. In binary classification, the
algorithm predicts a probability for the positive class that can be mapped to a binary
outcome by setting a threshold. The value of the threshold can be fixed (standard
approach); determined experimentally or computed using various approaches. The
standard approach is the default setting.
The LReg algorithm is widely employed for both classification and regression problems.
In a binary classification problem, like the one in this study, LReg predicts the
probability of a given instance (a data entry) belonging to a certain category or not. The
Liblinear library is among other types of solver in LReg. The solver is geared towards
binary classification, small to moderate sample size, and it supports L1 (Least Absolute
Shrinkage and Selection Operator, also known as LASSO) and L2 (Ridge) regularization
techniques. By default, Scikit Learn utilizes L2 as the regularization method in its logistic
regression. LReg uses a non-linear activation function, known as the sigmoid function, to
classify data. Many machine learning studies that model obstetric health problems such
as GDM [81] and metabolic syndrome [19] successfully explored logistic regression.
2.1.2.6.3. RANDOM FOREST
The Random Forest classifier is a tree-based supervised ensemble machine learning
algorithm that builds multiple decision trees from randomly explored and selected subsets
of its training data, then combines their outputs. It then harnesses the power of the trees
by aggregating their predictive votes to establish the final class of the test object. This
characteristic of RF contributes to its advantages over a single decision tree. The RF
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classifier is known for its high specificity and sensitivity; robustness to noise and outliers;
and rare overfitting or underfitting; two problems that may arise from noisy data. RF is
also computationally and time efficient (cost). Literature widely points to the optimality
of combining many estimators as a classification algorithm [82], [75]. Among many
clinical problems, RF was implemented for modeling in an acute kidney injury study
[83]. Also, in a comparative study of diabetes where machine learning models were
developed, both the LReg and RF classifiers performed similarly [84].
2.1.2.6.4. DECISION TREE
Another well-known Tree-based algorithm that is commonly used for supervised machine
learning is Decision Tree. It estimates or constructs a single tree that can be represented
in a flowchart-like tree structure. The topmost node in a decision tree is the root node, the
internal node represents feature (attribute), the branch connotes a decision rule, and each
leaf (terminal) node symbolizes the outcome. The classifier learns to partition the tree
based on the attribute value in terms of how much information a feature can provide the
sub-tree, thus calculating the Entropy (Section 2.1.2.2.3.2) or the Gini Impurity of such
feature (IG analysis). It splits the tree using recursive approach (recursive partitioning).
The flowchart-like structure assists in understanding the decision-making process of the
algorithm as the attributes that weighed most heavily in the classification are transparent.
Studies indicate one of the pitfalls of machine /deep learning model utilization in the
clinical domain is the lack of human interpretability of some of the algorithms, hence,
disease models are sometimes seeing as a black box [85]. In general, tree-based
estimators ameliorate this barrier as they balance human readability and interpretability
with efficiency, thus, adding value to the classification model. This characteristic bestows
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a wide acceptance advantage on tree-based models among the medical experts [86]. The
Decision Tree estimator has been employed in the health domain involving binary
classification task to identify the relationships of several predictors to an outcome
variable- metabolic syndrome [19], and GDM [87] for instance.
2.1.2.6.5. STACKINGCLASSIFIER
The StackingClassifier is a heterogeneous ensemble algorithm. The classifier combines
multiple classification algorithms through a meta-classifier. The base estimators, also
known as the first-level learners or weak learners, are trained on the entire training set.
The algorithm is implemented using cross validation. The meta learner (second-level
learner) gets fitted on the outputs of the base learners and the final prediction is then
computed by the meta-estimator, hence. There are two ways of utilizing Stack– training
the meta classifier on the predicted class labels or on the probabilities from the ensemble.
2.1.2.7. DEEP LEARNING ARCHITECTURE

Yes_GDHP (1)

No_GDHP (0)

Adapted from: Adhi Ta ma , Ba yu & Rhee, Kyung Hyune. (2017). Atta ck Cla ssifica tion Ana lysis of IoT Network
via Deep Lea rning Approa ch. Resea rch Briefs on Informa tion & Communica tion Technology Evolution
(ReBICTE). 3. 10.22667/ReBiCTE.2017.11.15.015.

Figure 2: Deep neural networks architecture
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A deep architecture/deep neural network (Figure 2) is a hierarchical, interconnected multiple
layers of three major processing units- input, hidden (more than one hidden layer), and output.
The concept simulates the human nervous system, thus having many nodes (neurons).
2.1.2.8. OVERVIEW OF DEEP LEARNING ALGORITHM
2.1.2.8.1. KERASCLASSIFIER
The KerasClassifier is a is Python compatible high-level deep neural networks API. It runs on
top of TensorFlow, and its core data structures are layers of nodes, each of which has an activation
function and parameters that are modified during training to create an optimal predictive model based
on the training data. KerasClassifier is a Keras wrapper library from Scikit Learn that can be used

for building deep network models for classification. The Keras-based classification algorithm
follows the typical DL architecture; hence, it is a multi-layer (input, hidden, and output) artificial
neural networks (ANN) variant. ANN, popularly known as “neural nets”, is a biology-inspired
data processing concept. There are various types of activation techniques (functions), but the
rectified linear unit (ReLU) and sigmoid functions dominate in binary classifications. Their
potential performance could be assessed over any number of epochs, as specified by a
hyperparameter given by the researcher. ReLU and Sigmoid functions are linear and non-linear
activation functions respectively. ANN algorithms have shown demonstrable success in the
obstetric modeling, such as [88], [78].
ReLU function: f(x) = max (0, x)

(3)

Deep learning is a subdomain of supervised machine learning, and ANN modelling that has seen
increasing use because it does not make assumptions about the independence or distribution of
feature values and hence can do well even without feature selection or data augmentation. Deep
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learning can also create decision models where relationships among features are non-linear, but
using multiple layers of nodes that each use the training data to learn optimal weights for
combining the inputs from other layers.
2.1.2.9. MODEL PERFORMANCE EVALUATION METRICS
Research supports using multiple measures to gauge and summarize model performance as no
single measure captures all the attributes of a model [89]. The techniques to use for such
assessment include model accuracy, F-score, precision, recall (sensitivity), and the area under the
receiver operating characteristic curve.
Key:
•

Positive (P): class instance is Positive

•

Negative (N): class instance is Negative

•

True Positive (TP): class instance is Positive, and the model predicted it as Positive.

•

False Negative (FN): class instance is Positive, but the model predicted it as Negative.

•

False Positive (FP): class instance is Negative, but the model predicted it as Positive.

•

False Positive Rate (FPR)

•

True Positive Rate (TPR)
2.1.2.9.1. PRECISION

Precision, also known as Positive Predictive Value (PPV), is the proportion of the correctly
predicted instances as belonging to class c among all class instances of which the classifier
claims that they belong to class c. So, this measure evaluates the fraction of correctly
classified instances among the instances classified as positive. It is mathematically expressed
as:
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Precision= TP/(TP+FP) *100

(4)

2.1.2.9.2. RECALL (SENSITIVITY)
Recall is the ratio (percentage) of the total number of class instances correctly classified as
positive instances, divided by the total number of class instances correctly classified as
positive, plus total number of class instances correctly classified as negative instances. High
recall score indicates the classifier has correctly identified many True positive class instances
and a small number of FN. Recall can be mathematically as:
Recall = TP/(TP+FN) *100

(5)

2.1.2.9.3. MODEL ACCURACY
The accuracy of a given algorithm is the overall correctness of the model. It refers to the
proportion of correctly predicted instances for each class to the total number of sample cases.
Therefore, the accuracy, A, of algorithm, m, can be mathematically expressed as:
Am=(s/N)*100

(6a)

, where s is the sum of correct predictions, and N is the total number of predictions made.
Or,

[(FP +FN)/(TP+TN+FP+FN)]

(6b)

It is cautionary to indicate that model accuracy could be a misleading model evaluation
metric, especially with an imbalanced data. So, the final decision about model performance is
not commonly based on this measurement.
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2.1.2.9.4. F1
The F1, also known as F-Measure, represents both precision and recall. It is the harmonic
mean of precision and recall. It uses the harmonic mean in place of the arithmetic mean to
regularize the extreme values more. F1 is mathematically expressed as:
F= (2*(Precision * Recall) /( Precision + Recall))

(7)

2.1.2.9.5. AREA UNDER THE RECEIVER OPERATOR CHARACTERISTIC CURVE
The area under the receiver operator characteristic curve of a model is an equivalence of the
c-statistic. This metric is a probability curve of the model ability to separate the positive class
from negative class. The measure is commonly being referred to as, AUC or ROC Curve. It
is used to display the performance of a binary classification algorithm, but it could be
modified for a multiclass as well. The closer the AUC score to 1 (maximum obtainable
score), the better; and that shows the model is a well-performing one with a high chance
(probability value) of good differentiation capability between positive and negative classes.
A poor model would have its AUC near 0; implying the algorithm has a worst measure of
separability (no class is selected). AUC score of 0.5 denotes the model is possibly merely
interchanging the result by predicting 0s as 1s and vice vasa. ROC Curve is normally plotted
with TPR against the FPR where TPR goes to the y-axis and FPR is on the x-axis.
2.2. RELATED STUDIES
2.2.1. RELATED MACHINE LEARNING BASED ANALYSES TO PREDICT GDHP
One of the few machine-learning based studies of GDHP has been that of Du et al (2020) [90],
where deep learning was the methodology of analysis. The authors conducted image analysis of
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unstructured data (radiology dataset; n=548) of fetal lung to investigate GDM and preeclampsia
individually and concurrently with the goal of predicting neonatal respiratory morbidity (NRM).
The focus of the study clearly differs from that of the present study as it was more fetal-oriented
than maternal, the dataset analyzed was unstructured data, and the sample size was small.
However, the current study centers on maternal risk identification for GDHP, and the commonly
obtained prenatal data was examined.
In a nationwide prospective study [82] carried out in Indonesia in the year 2020, the authors
adopted artificial intelligence (AI) techniques for a preliminary prediction of preeclampsia. The
study analyzed the data of the preeclamptic/eclamptic (n = 3318) vs pregnant women with
normal blood pressure (n = 19,883) with singleton pregnancy. There were 95 features in the
dataset, ranging from demographic data to past medical histories (from 24 months prior to the
event, to delivery as the event). Feature selection found only 17 predictors to be the most
influencing factors as identified by random forest. We plan to test this algorithm out in feature
selection processes of the GDHP modeling as well. SVM, LReg, DTree, RF, artificial neural
networks and an ensemble learner (a combination of all other mentioned algorithms) were the six
classification algorithms explored by the authors. AUC was employed to compare the models.
Finding from the study indicates pre-conceptual health around one year (“9-12 months to the
event”) is crucial to perinatal outcomes. Using precision, sensitivity, and specificity in the
validation sets, the model built in Sufriyana et al.’s work [82] outperformed the existing ones.
Although this obstetric modeling yielded a very informative result about preeclampsia
prevention, excluding women with other variants of HDP and the gestational diabetic
hypertensive (or vice versa) women is one of its limitations. This is especially the case;
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considering the assertion that the factors responsible for HDP variants are very similar, and that
the conditions carry an equal level of risk, which includes cardiovascular disease [4].
Additionally, SML methods were applied to a genome-wide association study (GWAS)
conducted by Kong and Choe (2019), where a female-specific metabolic syndrome predictive
model was constructed (n=3,968) [91]. The GWAS research was devoted to finding fundamental
genetic concepts in relation to MetSyn of the female gender. Model evaluation depicts the AUC
of the ROC curve for female is significantly higher (AUC = 0.85) than that of male
(AUC = 0.57). The results are consistent with literature as they imply that women are genetically
more susceptible to MetSyn than men [15], [92]. The study, however, was data-restrictive
because genetic risk factors were solely explored in the prediction of metabolic syndrome
affecting women, while studies show disparate non-causal factors are responsible for HDP. Also,
even though the study focused on women and MetSyn, pregnancy-related factors were not
examined.
2.2.2. RELATED NON-MACHINE LEARNING BASED ANALYSES TO PREDICT
GDHP

Earlier data-driven work on GDM and HDP co-occurrence did not use machine learning. Ling et
al. (2018) [93] carried out a prospective study using conventional statistical methods to ascertain
the individual and synergistic effect of GDM and HDP on postpartum cardio-metabolic risk. Of
the 400 pregnant women who were recruited at their early pregnancy period (5-8 weeks), 276 of
them eventually participated in the 5-year follow-up study. The authors described MetSyn as an
abnormal glucose metabolism and hypertension. The results of the study show HDP and GDM
individually and collectively impair postpartum cardiometabolic health. The study reported a
Relative Risk of 2.6 (1.7-3.9) and 2.7 (1.6-4.9) for each case (individual condition and jointly)
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respectively. Although, there is a thin line of difference between these relative ratios; with both
having approximately threefold risk ratio, their slight difference cannot be overlooked.
Meanwhile, due to the inherent drawbacks of the study design (longitudinal study), the result is
not generalizable. For instance, there is a 5-year gap between the time when the study
commenced and when it ended. Apart from the study recording nearly 50% (124 gravidae)
response loss, much could have changed in the participants’ health status (and /risk factors) after
the study started (during pregnancy), and after delivering their babies. For instance, some could
have embarked on lifestyle modification, as various studies indicate these changes are necessary
to prevent or minimize maternal cardiometabolic risk. The final sample size (276) is also too
small for the finding to be applicable to the pregnant population.
Another non-SML study within the paradigm of concurrent GDM and HDP was conducted in
2018 by Cao et al. [94]. The co-existence of gestational diabetes mellitus and preeclampsia using
the laboratory data (C-reactive protein (CRP) and interleukin-17/IL-35) was used, along with the
BMI of four groups of pregnant women (139). The groups were assembled according to
attributes, including preeclampsia, normal blood pressure, GDM and co-existing GDM and
preeclampsia. Multiple conventional low-level data analysis methods were applied, including
statistical significance of difference and Analysis of Variance with Post-hoc Turkey’s test to
assess the difference of means of the four groups. Pearson correlation coefficient was also
applied to examine the association between predictors. Its result shows there is a positive
correlation between the following variables diastolic blood pressure with interleukin (IL)-17
levels; BMI and triglyceride; and, between IL-17 levels with BMI and proteinuria in the group
with comorbidity of GDM and preeclampsia. Results from the analysis demonstrate maternal
hyperlipidemia (lipids), hyperglycemia, high BMI, high CRP levels and imbalanced interleukin-
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17/IL-35 may lead to the comorbidity of GDM and PE. This insight notwithstanding, the sample
size is too small, and its scope is limited. A myriad of factors determining the co-existence of
GDM and preeclampsia were left out by analyzing only maternal laboratory and BMI data. This
is especially so because as Gaillard et al.’s work [73] reveals, laboratory tests may fail in certain
situations; and its ability may not extend to certain risk factors of these diseases. However, the
finding from Cao et al.’s work is consistent with the other research indicating GDM and HDP
interrelate. It also shows the impact of GDHP extends beyond the pregnancy period.
2.2.3. SUMMARY OF RELATED DATA-DRIVEN STUDIES ON GDHP
As the discussed past machine learning research have shown, supervised machine learning
clearly holds promise for identifying pregnant women who are at risk of developing GDHP.
Generally, machine learning research centering on the comorbidity of GDM and HDP is rare.
Therefore, the current study adds to the body of knowledge, and its superiority is in in many
folds 1.) it is more comprehensive in terms of the disease component as it considers the six HDP
fields and one GDM field that are available in WiseSubset to create the comorbidity field; 2.) it
is also wide-ranging in methods because it simultaneously assessed the utility of five standard
SML and a deep learning algorithm on routine prenatal care attributes. To the best of our
knowledge, there is no published model that combines such methods to study GDHP; and 3.) this
is also the first research to classify the gravid population as having GDHP or not, using a PeriData
set or otherwise, and regardless of the methodology. These observations point to the uniqueness
of our research in the domains of machine learning and obstetrics.
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3. METHOD
3.1. INSTITUTIONAL REVIEW BOARD
We obtained an Institutional Review Board (IRB) approval (IRB No.21.250) from the University
of Wisconsin, Milwaukee before embarking on this research. We also had Data Use Agreements
with the clinical site. To be Health Insurance Portability and Accountability Act compliant, we
obtained a waiver for the two PHI fields in our research protocol. For the purpose of this
research, we named the sample as, “WiseSample”; and the extract of WiseSample was called,
“WiseSubset”. Some of the fields in the sample were smoking, prepregnancy weight, fetal
gender, mother’s blood group, mother’s calculated age, and mother’s reported age.

3.2. DATA PREPROCESSING
3.2.1. EXPLORATORY, DESCRIPTIVE DATA ANALYSIS AND DATA EXTRACTION
A custom program was written in the Python programming language to analyze the WiseSample
dataset for the binary classification of GDHP. We started the exploration of the WiseSample
dataset with 9962 data entries, each with 79 fields. We first renamed all the fields, and certain
value names that were not compatible with some of the data processing methods utilized in this
study were converted to numeric values. Exploratory analysis showed the sample was noisy, and
placeholder values were identified. We then replaced the placeholders with the token “Nan” for
missing value (MV)s, and filtered the DataFrame by excluding from the sample all instances that
lack an actual value for the following seven outcome fields used to determine the target
(comorbidity) field: Preeclampsia (2 fields), with or without severe features; gestational
hypertension (2 fields), from the maternal or from the child record; eclampsia (1 field); HELLP
33

syndrome (1 field); and gestational diabetes (1 field). This resulted in WiseSample having 4794
instances and 79 fields.
3.2.2. MISSING DATA ANALYSIS AND FEATURE ENGINEERING
There were fields with missing values or low frequency count values in WiseSample. We
merged some missing value fields to create a composite field appropriately. Such fields include
1.) the 13 substance-abuse-related fields in the sample (formed Combo_Subst_Use field);
smoking and secondhand smoking (created smoking_FirstSec field). In some fields with low
frequent count values, such as mother’s primary race, we merged such values to create a
combined value in their respective fields. This data manipulation increased the number of fields
to 82 before we dropped the original fields that were combined. We set and utilized a data
imputation threshold of a MV ≤ 30.00%, then applied the SimpleImputer method of Scikit Learn
to address the numeric and categorical missing data. We then dropped fields not meeting the
imputation cutoff point; the redundant fields; past obstetric history fields that were suggestive of
previous GDM/HDP (a delivery history of macrosomia for instance, indicates previous GDM);
and irrelevant fields (e.g. hysterotomy). In this phase, we were left with 4794 instances and 34
fields in the sample.
3.2.3. DATA EXTRACTION
We applied two study participation eligibility criteria: no prepregnancy diabetes, and no chronic
hypertension, and 4624 instances fulfilled the requirement, hence, WiseSample had 4624
instances and 34 fields. Next, we engineered a binary comorbidity field, GDHP” (Yes [1]/
No[0]) by merging the seven GDHP-related outcome fields, (Section 3.3.1), thus extracting the
WiseSubset dataset (4624 instances and 36 fields) from WiseSample. We then dropped the
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merged primary fields; the participation criteria; and the merged fields that persistently have low
frequent counts. The WiseSubset dataset then had 4624 instances and 24 fields.

3.2.4. DATA TRANSFORMATION
To normalize the numerical data, we utilized the MinMaxScaler method of Scikit Learn. We
transformed the continuous data in multiple steps into categorical data to engineer new fields
from their respective values. Mother’s reported age, husband’s reported age, prepregnancy
weight, and pre-pregnancy BMI were among the fields that benefitted from this operation.
Ordinal data such as mother’s educational status were transformed numerically to preserve and
reflect their natural order, while the nominal data was transformed into numerical data using the
LabelEncoder method of Scikit Learn as well.
3.2.5. FEATURE ENGINEERING
We carried out multiple feature engineering operations to create new fields from existing fields
where necessary, to reduce the sparsity among value types for some features of the WiseSubset
dataset and to add features that are implicit in the data, but not represented directly. Among such
operations was the creation of a “Season” field from the month part of the “date of first prenatal
care visit” field, and its four weather (United States) values were later turned into four new
binary fields. Also, the “Year” in the “date of first prenatal care visit” field was utilized with the
“Year of Last birth” field to engineer an interpregnancy interval field. The field of mother’s
height in feet and the inches part of the height value, which was a separate field were merged to
create a single field (feet.inches). We created two categorical fields from the new field.
Additionally, we followed the adult BMI classification of the CDC [95] to categorize the
prepregnancy BMI field, then, engineered five new fields from its five values. Mother’s reported
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age, and husband’s reported age were also decomposed into three age ranges respectively.
Another field that benefitted from this phase was prepregnancy weight, from which we created
three new fields (small, medium, large). We similarly transformed the gestational week at first
prenatal care visit field into three fields. In total, 24 new fields were derived from the existing
fields in this phase, we call them, “TheNew24”. We dropped all primary/intermediate fields that
were utilized during feature engineering, then, WiseSubset finally consisted of 4624 instances
with 38 features and 1 target field.
3.3. FEATURE SELECTION
We assessed the utility of four different feature selection techniques to select the optimal feature
subsets from the 38 features while the dataset was still imbalanced. The Scikit Learn pipeline
was used to implement the embedded FSTs: Recursive Feature Elimination, Recursive Feature
Elimination with Cross Validation, and the wrapper method (Genetic Algorithm). Pearson
Correlation Coefficient and Variance Inflation Factor Analysis was also examined.
3.3.1. PEARSON CORRELATION COEFFICIENT AND VARIANCE INFLATION
FACTOR ANALYSES
We started PCC-VIFA by obtaining a correlation matrix of the entire feature set (38), then, we
divided the features into three themes: Obstetric, Maternal-paternal profile, and Environmental,
and we obtained their correlation matrices. We then set three different thresholds for each of the
three sequential steps in this FST: feature-feature multicollinearity check, feature-target
correlation analysis, and an advanced multicollinearity analysis with VIF with the Statsmodel
Python library. For feature-feature pairwise correlation, we utilized a correlation coefficient (r)
threshold of abs(r < 0.75), thus giving considering both the positively and negatively correlated
features. We similarly applied a threshold of abs(r < 0.00) in the feature-target correlation. The
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intermediate result was an input data for VIF analysis, with a threshold: R Squared= 2.50.
Features not meeting the cutoff point were automatically dropped. The 19 features that were
finally selected by PCC-VIFA were named, “19PCC-VIFA”, and we later subjected them to
information gain analysis with random forest. The selected features were the input data for,
“Model Set 4”.
3.3.2. RECURSIVE FEATURE ELIMINATION
To implement RFE, we randomly split the data into 8:2 ratio of train and test sets. Then,
we utilized the GridSearchCV algorithm to find the best parameters and their values for
the GradientBoosting (XGB) classifier, which we used as an estimator inside the pipeline
of the RFE algorithm, hence, RFE-XGB. We then fitted the pipeline on the training set
and iterated over the range of the indices of the 38 features, starting from index 1. Model
performance was generated per iteration as the model made predictions on the test set. No
GDHP model was constructed through this FST.
3.3.3. GENETIC ALGORITHM
We first randomly split the data into 8:2 ratio of validation set, and TrainAndTest sets,
the latter was then split randomly as train-test sets. The genetic algorithm framework
employed was the Distributed Evolutionary Algorithms in Python (DEAP). We set the
initial population size to 0, initialized the weight with 1 and 0 for bias, and we set
population size to 100 per generation of 10. We implemented the tournament selection
method for choosing individuals from a population. The crossover probability was also
set to 0.5, and 0.2 for the mutation probability. A binary vector of 0 and 1 was created for
all the features, where 1 implies the corresponding feature would be selected by the
estimator, and 0 otherwise. We wrapped genetic algorithm on logistic regression, hence,
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Gen-LReg, to build a model per iteration. A test accuracy score (fitness score) was
obtained per iteration through a fitness function that evaluates each “individual”
(combination of features). The Genetic Algorithm stopped when the population
converged at an optimal solution, and that was an individual containing 22 features. We
named the predictors, “22Gen”, and obtained their importance scores with random forest.
A barh chart (a horizontal bar chart) was also generated to visualize their ranks. We
called the model set that utilized the “22Gen” as input data, “Model Set 5”.
3.3.4. RECURSIVE FEATURE ELIMINATION WITH CROSS-VALIDATION
We utilized 10-fold StratifiedKFold cross-validation to satisfy the cross-validation
parameter of the RFECV, while we passed random forest as its estimator, thereby
creating an ensemble feature selection. This method selected 9 features that we called,
“9RFECV-RF”. We obtained a Line chart for visualizing the CV scores and their
corresponding numbers of selected features. A barh chart was also plotted for feature
importance with RF. We utilized the 9RFECV-RF for constructing, “Model Set 6”.
3.4. DATA AUGMENTATION
We utilized SMOTE to resolve the class imbalance noted in the WiseSubset data exploration
phase. For the four (LReg, DTree, RF and SVM) of the five standard classifiers, we implemented
the resampling algorithm (SMOTE) on the “train” part of each of the stratified fold, thus
preserving the gold standard (“test” part of each fold). This was done through the Imblearn
pipeline. We, however, transformed the dataset externally with SMOTE when using Stack and
Keras since they have no pipelines. In both SMOTE implementation types, the resampler was
utilized both in its default and in an optimized mode. For clarity, we refer to the augmented
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training data per mode as, “Augmented Dataset1” and “Augmented Dataset2” respectively. To
optimize SMOTE, we tuned its k_neighbors (k) parameter by iterating over a range of k values
(1-10) to select the best value of k in SMOTE per classifier. We set the strategy parameter to
“auto” and examined the utility of the data augmentation algorithm through the models created
with each augmented dataset. While Augmented Dataset1 was used to construct the models that
we call, “Model Set 2”, its Augmented Dataset2 counterpart was utilized for creating Model Sets
3, 4, 5, and 6. Meanwhile, the Keras model was only included in Model Sets 2 and 3 with
SMOTE because FST outputs were the data input in the remaining four model sets, and feature
selection is not a separate process in DL.
3.5. CONFIGURING AND TESTING THE SUPERVISED MACHINE LEARNING
MODELS
We examined various models created using the following six types of classifiers: Logistic
regression, random forest, decision tree, support vector machine, StackingClassifier, including a
DL classifier known as KerasClassifier. All the algorithms, except the latter, were utilized in
both their default and optimized modes. For each classifier (except for Stack), we utilized an
hyperparameter tuning algorithm, known as GridSearchCV, to objectively search and find the
best hyperparameters and their values from a list of parameters and some corresponding values
that produce a model with good performance, thus optimizing the classifiers. We then examined
the configuration quality of the classification algorithms, using standard performance measures.
We developed a set of base models (Model Set 1) while the LReg, SVM, RF and DTree were in
their default states through their respective full Scikit Learn pipelines. Model Set 2 was similarly
built with the listed classifiers still in their default states, but Imblearn pipeline was utilized, and
SMOTE (default) was added. We constructed four different model sets (Model Sets 3-6) with the
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optimized classifiers (and an optimized SMOTE), all implemented through the Imblearn
pipelines of each of the classifiers. For the StackingClassifier, we set RF, DTree, and SVM as the
base learners, while LReg was utilized as the final estimator (meta learner). This configuration
was implemented and tested in 6 scenarios to build Model Set 1-6. The deep learning algorithm
was developed with KerasClassifier. The model was configured as follows: 4 layers of 1 input
layer (38 input data), 2 hidden layers, and 1 output layer. The layers had 16,16,16 and 1 node
respectively: with a corresponding ReLU activation function, except for the last layer where
Sigmoid was utilized as the activation function; an optimizer (Adam); a loss function (binary
crossentropy); and a scorer (accuracy).
For building the Keras baseline model, we used 400 epochs and 2000 batchsize, and the
imbalanced data was analyzed with the 38 features. We then tested the configuration with one
case, the baseline (Model Set 1). Then, we included hyperparameter tuning in the DL classifier
configuration of subsequent modeling by setting a range of epochs between 2 and 10, and
batchsize to 100 and 1000, and incorporated GSCV to automatically test and update the
respective values during learning. We tested the tuned configuration with Model Sets 2-3.
3.6. MODEL TRANSPARENCY WITH DECISION TREE

We constructed 33 decision tree models in this analysis. To promote transparency (Section
2.1.2.3.1), a single tree structure was obtained as a representation for visualization from the
model set where the DTree algorithm recorded the best performance (Model Set 4), based on
recall and AUC. This represents/ portrays the concept of model transparency that is common to
medical modeling, and Entropy (Section 2.1.2.3.2) was utilized in the DTree algorithm.
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3.7. SUMMARY OF EXPERIMENTS
All the six classifiers in this analysis utilized the full set of features in 18 scenarios (Model Sets
1-3), while we additionally tested each of the five standard SML algorithms using each of the
four derived feature sets from the FSTs in 15 scenarios (Model Sets 4-6). Therefore, a total
number of 33 predictive modeling scenarios were created in this binary classification of the
WiseSubset dataset for GDHP. The Sklearn pipeline was used in 4 (LReg, RF, DTree, and SVM in
Model Set 1) of the 33 tests, while the Imblearn pipeline was utilized 20 times. Testing Stack (6

cases) and Keras (3 cases) with no pipeline created the remaining 9 scenarios. The SKFCV
cross-validation method was applied to evaluate every model constructed. To measure and
summarize model performance, we utilized accuracy, F1, precision, recall (sensitivity), and
AUC; ROC plots were also generated. All the models in this research were systematically
designed and grouped by input data.
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4. RESULTS
4.1. DATASET
The exploratory analysis of WiseSample showed the dataset contained actual, missing, and
placeholder values. Missing data analysis also revealed 31.09% and 31.87% of the dataset had a
missing value (before and after replacing the placeholder values with a token “Nan” for missing
data). Part of the results (Figure 3) of the descriptive analysis of the WiseSample is the
imbalanced distribution of the seven outcome fields that were utilized in creating the GDHP.
This resulted in the class imbalance of the WiseSubset against the positive class as shown in the
GDHP chart inside Figure 3. The imbalance is approximately ratio 1.1:100 for the positive class
and the negative class respectively. Table 1 summarizes the descriptive results of the
WiseSubset, and the new 24 fields created during feature engineering are displayed in Table 2.
Also, a full list of the starting fields is available in Appendix A.
Table 1: Summary of descriptive analysis of WiseSubset
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Table 2: List of the new 24 features created in WiseSubset

4.2. FEATURE SELECTION
Using the RFE-XGB feature selection method, the test accuracy was 98.56% from index 1 to 38,
hence, this method selected no feature and, thus, no model set. The three steps in the PCC-VIFA
approach eliminated 6, 1 and 12 features respectively. The thresholds were abs(r<0.75),
abs(r<0.00), and R Squared=2.50 accordingly; and PCC-VIFA eventually selected 19 features.
The correlation matrices obtained are in Appendix C-F. The Gen-LReg method selected 22
features as the best explanatory factors for GDHP. The RFECV-RF strategy identified 9 best
features, and a Line chart displaying the cross-validation scores per number of features selected
is available in Figure 4. Also, a barh chart (horizontal bar chart) is in Figure 5 to visualize the
importance (normalized feature ranking) of the “9RFECV-RF” selections. The results of the
feature importance analysis conducted with random forest on each feature representative set
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selected by the three FSTs that selected a feature subset is in a combined Table (Table 3). There
is also a Table (Table 4) displaying the entire 38 features, and the selected features per feature
selection method, together with their non-normalized ranks. However, Appendix B is a unified
view of any information pertaining to all the features and their selections.

.

Figure 3: Multiple charts showing class imbalance of the GDHP field and its origins.
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Figure 4: Line chart of the RFECV-RF feature selection process

Table 3: Normalized feature ranking (importance) of the selected features per FST

.

.

45

.

Figure 5: Barh chart showing the importance of the features selected by RFECV-RF
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Table 4: All features, their selected subsets per FST, and their non-normalized ranks
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4.3. OVERALL MODEL COMPARISON
We used the following six SML algorithms; LReg, SVM, RF, DTree, Stack, and Keras for
constructing predictive multiple binary classification models for GDHP. The results of the
overall model comparison (Figure 6) show SVM recorded the best mean recall (100.00%) in
Model Set 6. The optimal features were identified by the RFECV-RF feature selection method
The ROC plot per model in Model Set 6 is available in Appendix G-K.
Figure 6: Results of overall model comparison

Overall Model Performance Comparison (SVM)
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4.4. MODEL PERFORMANCE COMPARISON BETWEEN ALL MODEL GROUPS
The results (Table 5) indicate Model Set 6 produced the largest mean recall score (100.00%)
through SVM, using the 9 features selected by the RFECV-RF feature selection method. The
highest mean AUC score recorded in this study was from Model Set 1, where LReg recorded
76.67% by utilizing the entire 38. Model Set 2 and 3 recorded the highest mean precision
(5.00%) through LReg as well. In both model sets, the 38 features were utilized with the
Augmented Dataset1 and Augmented Dataset2 respectively. For F1, its highest mean score was
from DTree Model Set 2 (4.93%), utilizing the Augmented Dataset1 and the 38 features.
Table 5: Results of comparison between all the classifiers assessed
Comparison Between The Six SML Algorithms Explored in Predicting GDHP

Classifier
SVM

Model Group

Accuracy

Precision

Recall

F1

AUC

Model
Model
Model
Model
Model
Model

Set
Set
Set
Set
Set
Set

1
2
3
4
5
6

98.94
94.81
55.93
64.77
52.68
1.19

0.00
2.61
0.58
1.43
0.86
1.06

0.00
8.00
25.50
46.50
39.00
100.00

0.00
3.87
1.13
2.78
1.69
2.10

49.69
67.03
36.57
54.98
46.20
48.62

Model
Model
Model
Model
Model
Model

Set
Set
Set
Set
Set
Set

1
2
3
4
5
6

98.94
98.57
98.79
80.02
85.99
73.47

0.00
5.00
5.00
1.53
2.05
2.31

0.00
2.00
2.00
26.50
22.00
57.00

0.00
2.86
2.86
2.78
3.68
4.44

76.67
65.14
69.67
54.98
69.73
48.19

Model
Model
Model
Model
Model
Model

Set
Set
Set
Set
Set
Set

1
2
3
4
5
6

98.94
98.92
98.70
87.15
90.94
85.23

0.00
0.00
0.00
1.29
2.38
1.11

0.00
0.00
0.00
12.00
12.50
16.00

0.00
0.00
0.00
2.28
3.85
2.07

60.67
64.71
72.10
58.91
65.50
66.27

Model
Model
Model
Model
Model
Model

Set
Set
Set
Set
Set
Set

1
2
3
4
5
6

97.19
97.45
92.06
76.58
80.25
76.28

3.08
4.44
2.58
1.86
1.91
1.47

6.00
6.00
16.50
39.00
35.00
36.50

4.05
4.93
4.39
3.52
3.85
2.82

52.08
52.21
59.62
61.09
60.38
56.64

Model
Model
Model
Model
Model
Model

Set
Set
Set
Set
Set
Set

1
2
3
4
5
6

98.50
97.42
86.53
79.11
79.81
80.15

0.77
1.08
0.93
1.37
1.30
1.40

1.50
3.00
1.37
24.38
18.38
28.38

1.01
1.56
1.60
2.51
2.24
2.66

60.59
70.23
72.06
58.43
64.54
64.30

Model Set 1
Model Set 2
Model Set 3

98.94
98.03
96.54

0.00
4.10
3.16

0.00
6.00
8.00

0.00
4.75
3.93

68.82
65.23
66.40

LReg

RF

DTree

Stack

Keras
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4.5. MODEL TRANSPARENCY: VISUAL INTERPRETATION OF DECISION TREE

The best mean recall (39.00%) recorded by the DTree algorithm in this analysis was from Model
Set 4), hence, we generated a representative DTree visualization (Figure 7) from this model set.
The diagram is a sample visualization of the information gain analysis (with Entropy criterion)
mechanism that the DTree uses in class assignment. We obtained the visualization from the 10th
iteration of the 10-fold StratifiedKFold cross-validation model evaluation method explored in
this study. To simplify the representation and enhance understanding, we limited the tree depth
to 3 (typically excluding the root node in the count), but the actual maximum depth utilized in
building the DTree model in Model Set 4 is 50. In the diagram below (Figure 7), infant gender
was automatically considered to be the root node because the DTree algorithm found the feature
as having the highest Entropy score (1.0), hence, the rule-based random split (True/False) starts
from the root node. Rules are human interpretable conditional statements used by the DTree
algorithm. The internal nodes (11) are where other features and their values were tested against
other partitioning rules. In total, the DTree tested 12 rules (including the root node). For the
dichotomous nodes (features with binary values e.g. 0,1), the data-split rule applied by the
classifier is the feature value ≤ 0.5. However, for the non-binarized categorical features
(mother_blood_group for instance) with nominal values (0, 1, 2, 3 values, representing the four
blood group types, ordered as {A, AB, B, O} for example), the algorithm decides and uses the
best splitting point that gives the minimum error. In the same mother_blood_group example, that
point was found in mother’s blood group value ≤ 2.5, which corresponds to the subset {A, AB,
B}. Thus, in Figure 7, the left branch corresponds to a blood type within this set, while the right
branch corresponds to a blood type outside the set, and that is, blood group O. The splitting point
of a feature may vary when evaluated in different subtree(s). “Samples” is the total number of
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instances in each node, and the number of instances per target class (“Yes_GDHP”, and “No_
GDHP”) after splitting is considered by the algorithm when deciding about intermediate class
assignment. A node with an even data split is regarded as an impure node (Entropy =1), hence,
the near the Entropy score to 1, the more the uncertainty or impurity of the node. A node with an
Entropy score nearing 0 is almost pure, and no further splitting is possible from a pure node (the
purer the node, the less the information needed for its description). Therefore, the DTree
algorithm continues to recursively traverse through the impure path(s) for further assessment,
splitting the data at any node possible. For the ultimate or overall class assignment, the DTree
classifier applies a majority rule to determine its prediction at the leaf nodes (1 leaf node is
shown below, generated by the Underweight_bmi node). Majority rule involves the assignment
of the most occurring class (mode) to a given instance.

Figure 7: A sample decision tree visualization
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4.6. ANSWERING RESEARCH QUESTIONS
4.6.1. RESEARCH QUESTION 1
As shown in Table 5, the best supervised machine learning tool for GDHP risk assessment was
designed using the features selected by the RFECV-RF feature selection approach (Model Set 6),
and not those identified by the Gen-LReg technique (Model Set 5). Therefore, there is a feature
selection method capable of outperforming Gen-LReg in identifying the optimal feature subsets
for modeling GDHP with the analyzed dataset, and that method is recursive feature elimination
with cross validation with random forest.
4.6.2. RESEARCH QUESTION 2
Based on recall, the results (Table 5) show the optimal SML model for predicting GDHP is
Support Vector Machine, thus, comparatively outperforming the Keras model on WiseSubset.
4.6.3. RESEARCH QUESTION 3
Compared to the model performance observed in Model Set 1 (Baseline); where the imbalanced
WiseSubset was utilized for GDHP modeling, all other model Sets; where the SMOTE algorithm
was applied, showed a demonstrable improvement (Table 5). Therefore, SMOTE was effective
in resolving the class imbalance, thus, improving WiseSubset for GDHP model construction.
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5. DISCUSSION OF RESULTS AND LIMITATION OF THE STUDY

5.1. DISCUSSION OF RESULTS
Considering our goal of designing a predictive SML tool (model) that optimally identifies the
sub-population of pregnant women who are at risk for GDHP using the routine prenatal
attributes, our model generalization and isolation decision was based on recall. The support
vector machine objectively emerged as the best model to predict GDHP. The model recorded a
mean recall score of 100.00%, utilizing the nine subsets of features selected by the recursive
feature elimination with cross-validation with random forest as input data. This optimal model,
however had a low precision score (1.06%, mean) as a tradeoff for recall, resulting in low mean
F1 score (2.10%), and six negative examples were correctly labelled. Therefore, an additional
screening step/further study may be needed to rule out the risk of GDHP in those falsely
identified (4569) as being likely to develop the comorbidity. During the experiments,
thresholding with Youden’s J-Statistic was assessed, but the method did not improve the model.
Furthermore, the feature ranking results (Table 2) show six of the nine most predictive factors of
GDHP identified by RFECV-RF were also among the top six selections made by at least one
other feature selection approach. This lends confidence to focusing on the six risk factors namely
healthy weight prepregnancy BMI, mother’s educational status, husband’s educational status,
husband’s occupation one year before the current pregnancy, mother’s blood group, and
mother’s age range between 34 and 44 years.
Healthy weight prepregnancy BMI (18.5-24.9kg/m2) ranked 5th among the 9 strongest risk
factors of GDHP, and it’s the 2nd of the 22 features selected by the Gen-LReg. We found the
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selection and the rank of this predictor to be the most striking exposition from this study. This
finding, however, agrees with prior assertions of a machine learning-based study on metabolic
syndrome of the general population [19], indicating that the non-obese do sometimes develop
metabolic impairments. With obesity being a traditional factor for GDM, HDP, and MetSyn,
there is a tendency for its presence (or the lack thereof) to be the sole consideration for GDHPrelated preventive/screening/interventional programs, thus increasing the chance of the pregnant
women with a prepregnancy BMI between 18.5-24.9kg/m2 not receiving timely assessment for
GDHP, a closely related disorder with metabolic syndrome. Mother’s and husband’s educational
statuses ranked second and sixth respectively among the nine most predictive factors of GDHP.
Although, the academic profile of a pregnant woman is as crucial as that of her husband in
lowering or eliminating the women’s risk of developing simultaneous occurrence of GDM and
HDP, that of the woman has a stronger influence. Both risk factors, however, belong to the same
theme (education), thus emphasizing the necessity for a joint effort of the educational and the
obstetric stakeholders over this impactful obstetric morbidity. Additionally, our study makes it
clear that mother’s blood group (4th of the 9 most predictive factors of GDHP) plays a crucial
role in predicting the co-existence of GDM and HDP. This finding is consistent with literature
indicating that maternal blood group is linked to HDP [48] and GDM individually [50].
Additionally, mother’s age (34-44 years) ranked 8th among the 9 most influencing factors of
GDHP. This finding is particularly useful for planning preventive/interventional targeted
programs against the comorbidity. The 9th strongest risk factor (husband’s occupation one year
before the current pregnancy) may be related to the family’s socio-economic status (income).
Lastly, the 1st (inter-pregnancy interval) and the 2nd (number of pregnancies plus current) of the 9
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best predictors, though they were only selected by RFECV-RF, are very important obstetric
factors associated with GDHP.
5.2. LIMITATION OF THE STUDY
This study has the following limitations: Both the sample size (9962) and that of its extracted subsample (4624) were small. The sample is also geographically limited to a hospital in WI, and the
site is a member of a database in the State of WI, therefore, we do not know how well the results
will generalize to other locales. Another limitation is the inability to identify the subset of
features utilized by the deep learner in constructing the Keras model, but this limitation is typical
of DL, hence, not a unique limitation of this research.
Lastly, based on literature, there are a few other GDM /HDP-related factors that may influence
the development of GDHP, but such information was unavailable in the analyzed dataset;
mother’s occupation is one of such data.
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6. CONCLUSION

We tested six commonly used supervised machine learning algorithms and a representative
model that employs a deep learning architecture. The results showed that our study has clinical
(obstetric) utility as such automated methods could be used to augment current prenatal
screening to find GDHP-at-risk expectant mothers who might not otherwise draw the attention of
their care provider, especially when they are 1.) primigravidas because such pregnant women
would have no previous obstetric history that could prompt their care providers for MCH
medical surveillance; and 2.) multigravidas with no GDHP-related past obstetric history.
Therefore, the designed GDHP model, the first of its kind, would likely improve pregnancy
outcomes; and ultimately be lifesaving for the gravidae and their unborn babies. The results of
this research would also potentially promote an effective targeted preventive /interventional care
plan; and resource distribution to the most needful (thus, saving costs) because our non-invasive
ML tool additionally identified the specific and the strongest non-causal factors of GDHP.
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